Key result
Moclobemide 200 mg twice daily remained neutral in the assessment of behavioural toxicity and did not disrupt sleep or cause daytime sedation in healthy elderly men.
Why the study?
Does moclobemide affect cognitive function and psychomotor performance in healthy elderly volunteers compared to placebo or amitriptyline?
RCT (n=12)
Does moclobemide affect cognitive function and psychomotor performance in healthy elderly volunteers compared to placebo or amitriptyline?
Moclobemide, unlike amitriptyline, does not impair cognitive or psychomotor function in healthy elderly volunteers.
No takes yet. Share an insight, caveat, or question.
May support moclobemide use in elderly without cognitive risk; leaves open confirmation in depressed patients.
Kerr et al. (1992) conducted an RCT in Healthy (n=12). Moclobemide vs. Amitriptyline 25 mg twice daily or placebo was evaluated on Cognitive function and psychomotor performance. Moclobemide 200 mg twice daily remained neutral in the assessment of behavioural toxicity and did not disrupt sleep or cause daytime sedation in healthy elderly men.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: